Leptin resistance before and after obesity: evidence that tissue glucose uptake underlies adipocyte enlargement and liver steatosis/steatohepatitis in Zucker rats from early-life stages.
Journal
International journal of obesity (2005)
ISSN: 1476-5497
Titre abrégé: Int J Obes (Lond)
Pays: England
ID NLM: 101256108
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
12
11
2020
accepted:
11
08
2021
revised:
26
07
2021
pubmed:
8
9
2021
medline:
19
2
2022
entrez:
7
9
2021
Statut:
ppublish
Résumé
Leptin resistance occurs in obese patients, but its independent contribution to adiposity and the accompanying metabolic diseases, i.e., diabetes, liver steatosis, and steatohepatitis, remains to be established. This study was conducted in an extreme model of leptin resistance to investigate mechanisms initiating diabetes, fat expansion, liver steatosis, and inflammatory disease, focusing on the involvement of glucose intolerance and organ-specific glucose uptake in brown and subcutaneous adipose tissues (BAT, SAT) and in the liver. We studied preobese and adult Zucker rats (fa/fa, fa/+ ) during fasting or glucose loading to assess glucose tolerance. Relevant pancreatic and intestinal hormonal levels were measured by Milliplex. Imaging of Preobese fa/fa pups showed impaired glucose tolerance, adipocyte enlargement, hepatic microsteatosis, and lobular inflammation, with elevated hepatic post-glucose load glucose uptake and production. Adult fa/fa rats had more severe glucose intolerance, fasting hyperglycemia, hormonal abnormalities, elevated glucose uptake in SAT and BAT, and more markedly in the liver, together with macrosteatosis, and highly prevalent hepatic inflammation. Organ glucose uptake was proportional to the degree of fat accumulation and tissue inflammation and was able to dissect healthy from NAFLD and NAFLD/NASH livers. Most severe NASH livers showed a decline in glucose uptake and liver enzymes. In fa/fa Zucker rats, leptin resistance leads to glucose intolerance, mainly due to hepatic glucose overproduction, preceding obesity, and explaining pancreatic and intestinal hormonal changes and fat accumulation in adipocytes and hepatocytes. Our data support the involvement of liver glucose uptake in the pathogenesis of liver inflammatory disease. Its potential as more generalized biomarker or diagnostic approach remains to be established outside of our leptin-receptor-deficient rat model.
Sections du résumé
BACKGROUND
Leptin resistance occurs in obese patients, but its independent contribution to adiposity and the accompanying metabolic diseases, i.e., diabetes, liver steatosis, and steatohepatitis, remains to be established. This study was conducted in an extreme model of leptin resistance to investigate mechanisms initiating diabetes, fat expansion, liver steatosis, and inflammatory disease, focusing on the involvement of glucose intolerance and organ-specific glucose uptake in brown and subcutaneous adipose tissues (BAT, SAT) and in the liver.
METHODS
We studied preobese and adult Zucker rats (fa/fa, fa/+ ) during fasting or glucose loading to assess glucose tolerance. Relevant pancreatic and intestinal hormonal levels were measured by Milliplex. Imaging of
RESULTS
Preobese fa/fa pups showed impaired glucose tolerance, adipocyte enlargement, hepatic microsteatosis, and lobular inflammation, with elevated hepatic post-glucose load glucose uptake and production. Adult fa/fa rats had more severe glucose intolerance, fasting hyperglycemia, hormonal abnormalities, elevated glucose uptake in SAT and BAT, and more markedly in the liver, together with macrosteatosis, and highly prevalent hepatic inflammation. Organ glucose uptake was proportional to the degree of fat accumulation and tissue inflammation and was able to dissect healthy from NAFLD and NAFLD/NASH livers. Most severe NASH livers showed a decline in glucose uptake and liver enzymes.
CONCLUSIONS
In fa/fa Zucker rats, leptin resistance leads to glucose intolerance, mainly due to hepatic glucose overproduction, preceding obesity, and explaining pancreatic and intestinal hormonal changes and fat accumulation in adipocytes and hepatocytes. Our data support the involvement of liver glucose uptake in the pathogenesis of liver inflammatory disease. Its potential as more generalized biomarker or diagnostic approach remains to be established outside of our leptin-receptor-deficient rat model.
Identifiants
pubmed: 34489524
doi: 10.1038/s41366-021-00941-z
pii: 10.1038/s41366-021-00941-z
doi:
Substances chimiques
Leptin
0
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
50-58Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Izquierdo AG, Crujeiras AB, Casanueva FF, Carreira MC. Leptin, obesity, and leptin resistance: where are we 25 years later? Nutrients. 2019;11:2704.
doi: 10.3390/nu11112704
Mazahreh TS, Alfaqih M, Saadeh R, Al-Zoubi NA, Hatamleh M, Alqudah A, et al. The effects of laparoscopic sleeve gastrectomy on the parameters of leptin resistance in obesity. Biomolecules. 2019;9:pii: E533.
doi: 10.3390/biom9100533
Salazar J, Chávez-Castillo M, Rojas J, Ortega A, Nava M, Pérez J, et al. Is “leptin resistance” another key resistance to manage in type 2 diabetes? Curr Diabetes Rev. 2020;16:733–49.
doi: 10.2174/1573399816666191230111838
Meek TH, Morton GJ. The role of leptin in diabetes: metabolic effects. Diabetologia. 2016;59:928–32.
doi: 10.1007/s00125-016-3898-3
Schmidt MI, Duncan BB, Vigo A, Pankow JS, Couper D, Ballantyne CM, et al. ARIC investigators. leptin and incident type 2 diabetes: risk or protection? Diabetologia. 2006;49:2086–96.
doi: 10.1007/s00125-006-0351-z
D’souza AM, Neumann UH, Glavas MM, Kieffer TJ. The glucoregulatory actions of leptin. Mol Metab. 2017;6:1052–65.
doi: 10.1016/j.molmet.2017.04.011
Fishman S, Muzumdar RH, Atzmon G, Ma X, Yang X, Einstein FH, et al. Resistance to leptin action is the major determinant of hepatic triglyceride accumulation in vivo. FASEB J. 2007;21:53–60.
doi: 10.1096/fj.06-6557com
Myers M Jr., Leibel RL, Seeley RJ, Schwartz MW. Obesity and leptin resistance: distinguishing cause from effect. Trends Endocrinol Metab. 2010;21:643–51.
doi: 10.1016/j.tem.2010.08.002
Turkenkopf IJ, Johnson PR, Greenwood MR. Development of pancreatic and plasma insulin in prenatal and suckling Zucker rats. Am J Physiol. 1982;242:E220–5.
pubmed: 7039359
Gruen R, Hietanen E, Greenwood MR. Increased adipose tissue lipoprotein lipase activity during the development of the genetically obese rat (fa/fa). Metabolism. 1978;27:1955–66.
doi: 10.1016/S0026-0495(78)80012-2
Lavau M, Bazin R, Guerre-Millo M. Increased capacity for fatty acid synthesis in white and brown adipose tissues from 7-day-old obese Zucker pups. Int J Obes. 1985;9:61–6.
pubmed: 3905649
Raymond B, Marcelle L, Colette G. Development of fatty acid-synthetic capacity in interscapudar brown adipose tissue during suckling in genetically obese Zucker rats. Biochem J. 1983;216:543–9.
doi: 10.1042/bj2160543
Pouteau E, Turner S, Aprikian O, Hellerstein M, Moser M, Darimont C, et al. Time course and dynamics of adipose tissue development in obese and lean Zucker rat pups. Int J Obes (Lond). 2008;32:648–57.
doi: 10.1038/sj.ijo.0803787
Phillips FC, Cleary MP. Metabolic measurements among homozygous (fa/fa) obese, heterozygous (Fa/fa) lean and homozygous (Fa/Fa) lean Zucker rat pups at 17 days of age. J Nutr. 1994;124:1230–7.
doi: 10.1093/jn/124.8.1230
York DA, Shargill NS, Godbole V. Serum insulin and lipogenesis in the suckling ‘fatty’ fa/fa rat. Diabetologia. 1981;21:143–8.
doi: 10.1007/BF00251282
Fürnsinn C, Komjati M, Madsen OD, Schneider B, Waldhäusl W. Lifelong sequential changes in glucose tolerance and insulin secretion in genetically obese Zucker rats (fa/fa) fed a diabetogenic diet. Endocrinology. 1991;128:1093–9.
doi: 10.1210/endo-128-2-1093
Apweiler R, Freund P. Development of glucose intolerance in obese (fa/fa) Zucker rats. Horm Metab Res. 1993;25:521–4.
doi: 10.1055/s-2007-1002165
Ionescu E, Sauter JF, Jeanrenaud B. Abnormal oral glucose tolerance in genetically obese (fa/fa) rats. Am J Physiol. 1985;248:E500–6.
pubmed: 3887938
Lean ME, Malkova D. Altered gut and adipose tissue hormones in overweight and obese individuals: cause or consequence? Int J Obes (Lond). 2016;40:622–32.
doi: 10.1038/ijo.2015.220
Guzzardi MA, Sanguinetti E, Bartoli A, Kemeny A, Panetta D, Salvadori PA, et al. Elevated glycemia and brain glucose utilization predict BDNF lowering since early life. J Cereb Blood Flow Metab. 2018;38:447–55.
doi: 10.1177/0271678X17697338
Iozzo P, Gastaldelli A, Järvisalo MJ, Kiss J, Borra R, Buzzigoli E, et al. 18F-FDG assessment of glucose disposal and production rates during fasting and insulin stimulation: a validation study. J Nucl Med. 2006;47:1016–22.
pubmed: 16741312
Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Nonalcoholic steatohepatitis clinical research network. design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–21.
doi: 10.1002/hep.20701
Chan CB, Lowe JM, Debertin WJ. Modulation by glucose of insulin secretion and glucose phosphorylating activity in cultured pancreatic islets from obese (fa/fa) Zucker rats. Int J Obes Relat Metab Disord. 1996;20:175–84.
pubmed: 8646255
Lee E, Miedzybrodzka EL, Zhang X, Hatano R, Miyamoto, Kimura I, et al. Diet-induced obese mice and leptin-deficient lepob/ob mice exhibit increased circulating GIP levels produced by different mechanisms. Int J Mol Sci. 2019;20:4448.
Chan CB, Pederson RA, Buchan AM, Tubesing KB, Brown JC. Gastric inhibitory polypeptide and hyperinsulinemia in the Zucker (fa/fa) rat: a developmental study. Int J Obes. 1985;9:137–46.
pubmed: 3897081
Ashwell M. The use of the adipose tissue transplantation technique to demonstrate that abnormalities in the adipose tissue metabolism of genetically obese mice are due to extrinsic rather than intrinsic factors. Int J Obes. 1985;9:77–82.
pubmed: 3905651
Guzzardi MA, Hodson L, Guiducci L, La Rosa F, Salvadori PA, Burchielli S, et al. The role of glucose, insulin and NEFA in regulating tissue triglyceride accumulation: Substrate cooperation in adipose tissue versus substrate competition in skeletal muscle. Nutr Metab Cardiovasc Dis. 2017;27:956–63.
doi: 10.1016/j.numecd.2017.08.002
Adeva-Andany MM, Pérez-Felpete N, Fernández-Fernández C, Donapetry-García C, Pazos-García C. Liver glucose metabolism in humans. Biosci Rep. 2016;36:e00416.
doi: 10.1042/BSR20160385
Mota M, Banini BA, Cazanave SC, Sanyal AJ. Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease. Metabolism. 2016;65:1049–61.
doi: 10.1016/j.metabol.2016.02.014
Kanda T, Matsuoka S, Yamazaki M, Shibata T, Nirei K, Takahashi H, et al. Apoptosis and non-alcoholic fatty liver diseases. World J Gastroenterol. 2018;24:2661–72.
doi: 10.3748/wjg.v24.i25.2661
Love C, Tomas MB, Tronco GG, Palestro CJ. FDG PET of infection and inflammation. Radiographics. 2005;25:1357–68.
doi: 10.1148/rg.255045122
Rudd JH, Myers KS, Bansilal S, Machac J, Pinto CA, Tong C, et al. Atherosclerosis inflammation imaging with F-18-FDG PET: Carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. J Nucl Med. 2008;49:871–8.
doi: 10.2967/jnumed.107.050294
Borra R, Lautamaki R, Parkkola R, Komu M, Sijens PE, Hallsten K, et al. Inverse association between liver fat content and hepatic glucose uptake in patients with type 2 diabetes mellitus. Metabolism-Clinical and Experimental. 2008;57:1445–51.
doi: 10.1016/j.metabol.2008.05.015
Abikhzer G, Alabed YZ, Azoulay L, Assayag J, Rush C. Altered hepatic metabolic activity in patients with hepatic steatosis on FDG PET/CT. American Journal of Roentgenology. 2011;196:176–80.
doi: 10.2214/AJR.10.4679
Lin CY, Lin WY, Lin CC, Shih CM, Jeng LB, Kao CH. The negative impact of fatty liver on maximum standard uptake value of liver on FDG PET. Clinical Imaging. 2011;35:437–41.
doi: 10.1016/j.clinimag.2011.02.005
Sarkar S, Corwin MT, Olson KA, Stewart SL, Liu CH, Badawi RD, et al. Pilot study to diagnose nonalcoholic steatohepatitis with dynamic 18F-FDG PET. AJR Am J Roentgenol. 2019;212:529–37.
doi: 10.2214/AJR.18.20012
Wang G, Corwin MT, Olson K, Badawi RD, Sarkar S. Dynamic PET of human liver inflammation: impact of kinetic modeling with optimization-derived dual-blood input function. Phys Med Biol. 2018;63:155004.
doi: 10.1088/1361-6560/aac8cb